Key SignalChem recombinant COVID19 antibodies for diagnostic research and development of anti-COVID19 treatments

SARS-CoV-2 virions have essential structural proteins it utilizes for various molecular mechanisms such as interacting with the host cell receptors, viral entry, and replication. SARS-CoV-2 exhibits two key structural proteins called the Spike (S) protein and Nucleocapsid (N) protein, the spike protein is utilized by the virus to attach itself to the host cell membrane and the N protein is necessary for transcription and replication. Both these mechanisms are key reasons for the instigation of infection, and disease complexities.

Image Credit: Shutterstock/Andrii Vodolazhskyi

The human body starts to produce antibodies against these two structural proteins immediately after the infection. The COVID19 specific immunoglobulins are important immune molecules used for both diagnostic purposes and to develop therapeutic interventions against the virus. To better understand the infection and the virus, antibodies produced by the body against these two structural viral proteins are well studied by scientists as it provides important molecular tools for diagnosis and treatments.

High-quality recombinant Anti-SARS-CoV-2 Spike (S) and (N) proteins, together can help researchers expedite their anti-Covid19 research by providing insights that could help guide the development of safe diagnostic tests, vaccines, and antibody-oriented treatments for the COVID19.

Anti 2019-nCoV N-Protein hIgG Antibody 

CoV N-Protein / Nucleocapsid protein is an RNA-binding protein primarily involved in binding to the viral RNA genome during the packaging of viral RNA into a helical ribonucleoprotein or nucleocapsid structure.  In addition, N-protein regulates viral RNA synthesis during replication/transcription and modulates host-pathogen interactions, such as actin reorganization, host cell cycle progression, and apoptosis.

The image shows the binding of Anti-2019-nCoV N-Protein Antibody (C19NP-60H) to immobilized 2019-nCoV N-Protein (C19NP-G242H) determined by ELISA using Goat anti-human Fc.

Image Credit: Signal Chem

N-Protein is abundantly expressed during infection and antibodies against N-Protein have been detected in confirmed cases of Covid-19. Therefore, N-Protein is a potent antigen that provides the basis for future vaccine and diagnostic kit development.

Anti 2019-nCoV Spike Protein hIgA Antibody 

The Spike Glycoprotein (S) of coronavirus belongs to the type I transmembrane protein containing two subunits, S1 and S2, which is also known to be the key component to bind with host cells through the interaction with angiotensin-converting enzyme 2 (ACE2). A receptor-binding domain (RBD) of S1 can recognize the cell surface receptor and the mutation of RBD could cause a higher motility rate.

The image shows binding of Anti-2019-nCoV Spike protein, IgA (C19S1-A60H) to immobilized 2019-nCoV Spike protein RBD (C19SD-G241H) determined by ELISA.

Image Credit: Signal Chem

Check out our full range of COVID19 antibodies and related products here.

About Signalchem

SignalChem is a Canadian biotech company focused on the research, development, and production of innovative and high-quality human recombinant cell signaling products.

Throughout the years, Signalchem has capitalized on its core expertise in cellular signaling, molecular biology, and protein biochemistry to generate more than 2,000 functional protein products and has established itself as the leader in the industry to produce highly active human recombinant signaling enzymes, especially protein kinases, disease-related mutant kinases, lipid kinases, epigenetic enzymes, ubiquitination-related enzymes, and neurodegenerative disease-related enzymes and proteins.

SignalChem strives to support scientists in academia, pharma, and biotech companies around the world by creating effective research tools to advance the basic research in life sciences and to facilitate the efforts in drug discovery and development.

Last updated: Nov 4, 2020 at 6:08 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    SignalChem Biotech Inc.. (2020, November 04). Key SignalChem recombinant COVID19 antibodies for diagnostic research and development of anti-COVID19 treatments. News-Medical. Retrieved on November 27, 2020 from https://www.news-medical.net/whitepaper/20201103/Key-SignalChem-recombinant-COVID19-antibodies-for-diagnostic-research-and-development-of-anti-COVID19-treatments.aspx.

  • MLA

    SignalChem Biotech Inc.. "Key SignalChem recombinant COVID19 antibodies for diagnostic research and development of anti-COVID19 treatments". News-Medical. 27 November 2020. <https://www.news-medical.net/whitepaper/20201103/Key-SignalChem-recombinant-COVID19-antibodies-for-diagnostic-research-and-development-of-anti-COVID19-treatments.aspx>.

  • Chicago

    SignalChem Biotech Inc.. "Key SignalChem recombinant COVID19 antibodies for diagnostic research and development of anti-COVID19 treatments". News-Medical. https://www.news-medical.net/whitepaper/20201103/Key-SignalChem-recombinant-COVID19-antibodies-for-diagnostic-research-and-development-of-anti-COVID19-treatments.aspx. (accessed November 27, 2020).

  • Harvard

    SignalChem Biotech Inc.. 2020. Key SignalChem recombinant COVID19 antibodies for diagnostic research and development of anti-COVID19 treatments. News-Medical, viewed 27 November 2020, https://www.news-medical.net/whitepaper/20201103/Key-SignalChem-recombinant-COVID19-antibodies-for-diagnostic-research-and-development-of-anti-COVID19-treatments.aspx.

Other White Papers by this Supplier